Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.
Also called NCT03785405
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 216 participants
- Sponsor
- Registry
-
NCT03785405
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Bulgaria, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, India, Israel, Italy, Japan, Lebanon, Poland, Portugal, Russia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT03785405. Allocation not applicable; no masking; primary purpose treatment. Start 2019-05-02 (actual); primary completion 2023-12-29 (actual). Results posted on 2024-07-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
- Condition
- Heart Failure
- Intervention (Drug)
- sacubitril/valsartan
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct03785405- Content hash
84b3b47fe48b7d4b666c777dde4648f348359e9c5695a44cc022f98dfb24c48f